Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
Clinically available KRAS* inhibitors and IO agents alleviated the immunosuppressive tumor microenvironment in PDAC. Profound tumor regression and prolonged survival in an autochthonous PDAC model provide a compelling rationale for combining KRAS* inhibition with IO agents targeting multiple arms of the immunity cycle to combat PDAC.
Authors
- Ronald A. DePinho (ORCID: https://orcid.org/0000-0002-5625-577X)
- Wen‐Hao Hsu (ORCID: https://orcid.org/0000-0001-9050-8227)
- Pingna Deng (ORCID: https://orcid.org/0000-0001-9716-4113)
- Paulino Tallón de Lara (ORCID: https://orcid.org/0000-0001-7368-4798)
- Li Cai (ORCID: https://orcid.org/0000-0002-2160-5055)
- Xiaoying Shang (ORCID: https://orcid.org/0009-0004-2398-4855)
- Kyle A. LaBella (ORCID: https://orcid.org/0000-0002-0473-9262)
- Shan Jiang (ORCID: https://orcid.org/0000-0002-2042-5298)
- Jincheng Han (ORCID: https://orcid.org/0000-0002-7751-6158)
- Yonghong Liu (ORCID: https://orcid.org/0000-0003-2609-7720)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Stanford Medicine (US)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1158/2159-8290.cd-24-0489
- Citations
- 21
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 5.05
Funders
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute